Matthew Matasar, MD, discussed what the findings from the ELM-1 trial of odronextamab in diffuse large B-cell lymphoma mean ...

Development strategies designed to reduce the unknowns so that cell and gene therapy innovators can develop robust processes ...

Biotherapeutics announced promising preclinical results for its systemic RTNova platform. The platform has successfully delivered ...

Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing a new generation of targeted antitumor virotherapies, today announced promising ...

LONDON, UK & CHICAGO, IL, USA I March 05, 2025 I Anova Enterprises, Inc. (Anova), a technology-enabled CRO dedicated to accelerating promising treatments, ...

In February 2024 a putative class action complaint against Molecular Partners, its directors, and certain of its executive officers, originally filed in July 2022 in the U.S. District Court for the ...

In an earlier study, patients with biomarker-positive high-grade glioma lived longer after treatment with DB107 than biomarker-negative patients.

Lentitek has secured £700,000 in private funding from Equity Gap, bringing its total investment to £1m in the last six months ...

A SCOTTISH biotech company has secured £700,000 in private funding, bringing its total investment to £1m in the last six ...

Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced ...

This study combines mathematical models and experimental data to analyse the emergence of heterogeneity within clonal NK cell responses during antigen-specific cell expansion. Although it comprises ...

Feb. 6, 2025 — Scientists have created a new low-cost, fast response sensor to detect lung cancer biomarkers, paving the way for the development of screening devices to spot the disease even ...